Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levodopa/carbidopa/entacapone - Orion

Drug Profile

Levodopa/carbidopa/entacapone - Orion

Alternative Names: ODM-101

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orion
  • Class Amides; Antiparkinsonians; Catecholamines; Catechols; Hydrazines; Nitriles; Nitrophenols; Small molecules
  • Mechanism of Action Catechol O-methyltransferase inhibitors; Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 21 Mar 2013 Efficacy & adverse events data from a phase II trial in Parkinson's disease presented at the 65th Annual Meeting of the American Academy of Neurology (AAN-2013)
  • 24 Oct 2012 Levodopa/carbidopa/entacapone - Orion is available for licensing as of 30 Sep 2012. http://www.orion.fi/
  • 23 Oct 2012 Efficacy data from a phase II trial in Parkinson's disease released by Orion
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top